Update on head and neck cancer: Current knowledge on epidemiology, risk factors, molecular features and novel therapies

Francesca Pezzuto, Luigi Buonaguro, Francesco Caponigro, Franco Ionna, Noemy Starita, Clorinda Annunziata, Franco M. Buonaguro, Maria Lina Tornesello

Research output: Contribution to journalArticle

Abstract

Tobacco use and alcohol consumption are the main risk factors associated with head and neck squamous cell carcinoma (SCC) development due to their cytotoxic and mutagenic effects on the exposed epithelia of the upper aerodigestive tract. Epstein-Barr virus (EBV) and high-risk human papillomaviruses (HPVs), both encoding viral oncoproteins able to interfere with cell cycle control, have been recognized as the etiological agents of nasopharynx carcinoma and a fraction of oropharyngeal carcinoma, respectively. Head and neck SCC is a deadly disease and despite innovative treatments represents a major challenge for patients. Recently, a number of genomic studies have highlighted the molecular heterogeneity of head and neck SCC based on methylation profiles, microRNA expression, mutated genes and new druggable pathways which may represent new targets for cancer-tailored therapies. To date, cetuximab is the only FDA-approved anti-epidermal growth factor receptor therapy for the treatment of head and neck SCC. In addition, a number of monoclonal antibodies targeting AKT, mTOR and PI3K pathways are under evaluation. Several therapeutic vaccines against HPV16 and EBV proteins are also under study. The purpose of this article is to review the epidemiology, pathogenesis and molecular features of head and neck SCC, with an emphasis on new therapies.

Original languageEnglish
Pages (from-to)125-136
Number of pages12
JournalOncology
Volume89
Issue number3
DOIs
Publication statusPublished - Aug 21 2015

Fingerprint

Head and Neck Neoplasms
Epidemiology
Tobacco Use
Human Herpesvirus 4
Therapeutics
Carcinoma
Nasopharynx
Molecular Epidemiology
Oncogene Proteins
Cell Cycle Checkpoints
MicroRNAs
Phosphatidylinositol 3-Kinases
Epidermal Growth Factor Receptor
Alcohol Drinking
Methylation
Vaccines
Epithelium
Monoclonal Antibodies
Carcinoma, squamous cell of head and neck
Gene Expression

Keywords

  • Epstein-Barr virus
  • Head and neck cancer
  • Human papillomavirus
  • Tumorigenesis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Update on head and neck cancer : Current knowledge on epidemiology, risk factors, molecular features and novel therapies. / Pezzuto, Francesca; Buonaguro, Luigi; Caponigro, Francesco; Ionna, Franco; Starita, Noemy; Annunziata, Clorinda; Buonaguro, Franco M.; Tornesello, Maria Lina.

In: Oncology, Vol. 89, No. 3, 21.08.2015, p. 125-136.

Research output: Contribution to journalArticle

@article{45b5b4349f1b40129f46d54e353931d5,
title = "Update on head and neck cancer: Current knowledge on epidemiology, risk factors, molecular features and novel therapies",
abstract = "Tobacco use and alcohol consumption are the main risk factors associated with head and neck squamous cell carcinoma (SCC) development due to their cytotoxic and mutagenic effects on the exposed epithelia of the upper aerodigestive tract. Epstein-Barr virus (EBV) and high-risk human papillomaviruses (HPVs), both encoding viral oncoproteins able to interfere with cell cycle control, have been recognized as the etiological agents of nasopharynx carcinoma and a fraction of oropharyngeal carcinoma, respectively. Head and neck SCC is a deadly disease and despite innovative treatments represents a major challenge for patients. Recently, a number of genomic studies have highlighted the molecular heterogeneity of head and neck SCC based on methylation profiles, microRNA expression, mutated genes and new druggable pathways which may represent new targets for cancer-tailored therapies. To date, cetuximab is the only FDA-approved anti-epidermal growth factor receptor therapy for the treatment of head and neck SCC. In addition, a number of monoclonal antibodies targeting AKT, mTOR and PI3K pathways are under evaluation. Several therapeutic vaccines against HPV16 and EBV proteins are also under study. The purpose of this article is to review the epidemiology, pathogenesis and molecular features of head and neck SCC, with an emphasis on new therapies.",
keywords = "Epstein-Barr virus, Head and neck cancer, Human papillomavirus, Tumorigenesis",
author = "Francesca Pezzuto and Luigi Buonaguro and Francesco Caponigro and Franco Ionna and Noemy Starita and Clorinda Annunziata and Buonaguro, {Franco M.} and Tornesello, {Maria Lina}",
year = "2015",
month = "8",
day = "21",
doi = "10.1159/000381717",
language = "English",
volume = "89",
pages = "125--136",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Update on head and neck cancer

T2 - Current knowledge on epidemiology, risk factors, molecular features and novel therapies

AU - Pezzuto, Francesca

AU - Buonaguro, Luigi

AU - Caponigro, Francesco

AU - Ionna, Franco

AU - Starita, Noemy

AU - Annunziata, Clorinda

AU - Buonaguro, Franco M.

AU - Tornesello, Maria Lina

PY - 2015/8/21

Y1 - 2015/8/21

N2 - Tobacco use and alcohol consumption are the main risk factors associated with head and neck squamous cell carcinoma (SCC) development due to their cytotoxic and mutagenic effects on the exposed epithelia of the upper aerodigestive tract. Epstein-Barr virus (EBV) and high-risk human papillomaviruses (HPVs), both encoding viral oncoproteins able to interfere with cell cycle control, have been recognized as the etiological agents of nasopharynx carcinoma and a fraction of oropharyngeal carcinoma, respectively. Head and neck SCC is a deadly disease and despite innovative treatments represents a major challenge for patients. Recently, a number of genomic studies have highlighted the molecular heterogeneity of head and neck SCC based on methylation profiles, microRNA expression, mutated genes and new druggable pathways which may represent new targets for cancer-tailored therapies. To date, cetuximab is the only FDA-approved anti-epidermal growth factor receptor therapy for the treatment of head and neck SCC. In addition, a number of monoclonal antibodies targeting AKT, mTOR and PI3K pathways are under evaluation. Several therapeutic vaccines against HPV16 and EBV proteins are also under study. The purpose of this article is to review the epidemiology, pathogenesis and molecular features of head and neck SCC, with an emphasis on new therapies.

AB - Tobacco use and alcohol consumption are the main risk factors associated with head and neck squamous cell carcinoma (SCC) development due to their cytotoxic and mutagenic effects on the exposed epithelia of the upper aerodigestive tract. Epstein-Barr virus (EBV) and high-risk human papillomaviruses (HPVs), both encoding viral oncoproteins able to interfere with cell cycle control, have been recognized as the etiological agents of nasopharynx carcinoma and a fraction of oropharyngeal carcinoma, respectively. Head and neck SCC is a deadly disease and despite innovative treatments represents a major challenge for patients. Recently, a number of genomic studies have highlighted the molecular heterogeneity of head and neck SCC based on methylation profiles, microRNA expression, mutated genes and new druggable pathways which may represent new targets for cancer-tailored therapies. To date, cetuximab is the only FDA-approved anti-epidermal growth factor receptor therapy for the treatment of head and neck SCC. In addition, a number of monoclonal antibodies targeting AKT, mTOR and PI3K pathways are under evaluation. Several therapeutic vaccines against HPV16 and EBV proteins are also under study. The purpose of this article is to review the epidemiology, pathogenesis and molecular features of head and neck SCC, with an emphasis on new therapies.

KW - Epstein-Barr virus

KW - Head and neck cancer

KW - Human papillomavirus

KW - Tumorigenesis

UR - http://www.scopus.com/inward/record.url?scp=84942190711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942190711&partnerID=8YFLogxK

U2 - 10.1159/000381717

DO - 10.1159/000381717

M3 - Article

C2 - 25967534

AN - SCOPUS:84942190711

VL - 89

SP - 125

EP - 136

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -